Cetuximab

Cetuximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	EGF receptor
Clinical data
Trade names	Erbitux
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cetuximab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01FE01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	114 hrs
Identifiers
CAS Number	205923-56-4 ;
DrugBank	DB00002 ;
ChemSpider	none;
UNII	PQX0D8J21J;
KEGG	D03455 ;
ChEMBL	ChEMBL1201577 ;
CompTox Dashboard (EPA)	DTXSID0040830 ;
Chemical and physical data
Formula	C6484H10042N1732O2023S36
Molar mass	145781.92 g·mol−1
	(what is this?) (verify)

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.

Cetuximab was approved for medical use in the United States in 2004.